There are no products listed under this category.
Welcome to CM Online Store!
Antibody Drug Conjugate Kits!
AqT bioconjugates coming soon!
CellMosaic offers research and process development services for diagnostic or medical imaging companies interested in developing highly specific diagnostic bioconjugates. CellMosaic's scientists have extensive experience in developing fluorescent-, antibody-, peptide-, and oligonucleotide-based detection agents. We provide a complete solution for the development of your diagnostic bioconjugate, including:
1. Antibody- and Antibody Fragment-Based Agent
Based on the unique conjugation strategy developed at CellMosaic, we offer site-specific antibody labeling and conjugation for diagnostic companies. A small detection agent or biopolymer can be conjugated to an antibody at a specific site away from the antigen binding site.
Comparison of labeling technologies:
Traditional antibody labeling technologies usually take advantage of the multiple Lys groups located in the antibody. Modification of the Lys groups changes the overall pI of the antibody and leads to higher nonspecific binding. In addition, if some of the modified or conjugated Lys residues are located on the antigen binding sites this method may produce partially active or inactive antibody conjugates that may not bind to the antigen.
Disadvantages of traditional Lys labeling technology are:
Advantages of CellMosaic's site-specific labeling technology:
2. Epitope-Based Detection:
CellMosaic prepares peptide-epitope conjugates based on a unique conjugation strategy developed at CellMosaic. Detection molecules can be conjugated anywhere on the peptide (C-terminus, N-terminus, or in the middle). Usually, a single, pure bioconjugate can be obtained. The whole process can easily be tailored to fit a client's project. This is a fast approach and great solution for clients who want to develop peptide-based conjugates.
Advantages of CellMosaic's peptide conjugation strategy:
3. Enzyme-Based Bioconjugates
Using the unique conjugation strategy developed at CellMosaic, we offer site-specific enzyme labeling and conjugation for diagnostic companies. A small detection agent or biopolymer can be conjugated to an enzyme at a specific site.
Comparison of labeling technologies:
Conventional labeling technology usually takes advantage of the multiple Lys groups located in the enzyme. Modification of the Lys groups changes the overall pI of the enzyme and leads to higher nonspecific binding.
Disadvantages of conventional Lys labeling technology are:
Advantages of CellMosaic's site-specific labeling technology:
4. Oligonucleotide-Based Bioconjugates
CellMosaic offers versatile oligonucleotide labeling and conjugation strategies, depending on the application profile of the diagnostic companies' reagent portfolio. A small detection agent or biopolymer can be conjugated to any site of the oligonucleotide (3', 5', or via a modified base). The conjugation can be done in either the solid phase or post-synthesis solution phase.
Please contact us to discuss your project.
Selected examples of diagnostic bioconjugates made at CellMosaic:
There are no products listed under this category.